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1. INTRODUCTION {#cam41819-sec-0005}
===============

Cetuximab is an IgG1 monoclonal antibody (mAb) that targets theepidermal growth factor receptor (EGFR) and has been shown to improve outcomes in patients with metastatic wild‐type *KRAS* colorectal carcinoma.[1](#cam41819-bib-0001){ref-type="ref"}, [2](#cam41819-bib-0002){ref-type="ref"} As many of these patients do not benefit from cetuximab treatment,[2](#cam41819-bib-0002){ref-type="ref"} there is an unmet need for additional predictive biomarkers, in addition to *RAS* and *BRAF* mutations.

One of cetuximab\'s mechanisms of action is antibody‐dependent cellular cytotoxicity (ADCC).[3](#cam41819-bib-0003){ref-type="ref"}, [4](#cam41819-bib-0004){ref-type="ref"} ADCC is initiated when the antigen‐binding fragment (Fab) binds to the tumor cell and the crystallizable fragment (Fc) binds to the crystallizable fragment gamma receptor (FCGR) on a natural killer cell, macrophage, or monocyte, creating a bridge from the tumor cell to the effector cell. Tumor cell recognition is then coupled with a lytic attack on the cancer cell mounted by effector cells.[5](#cam41819-bib-0005){ref-type="ref"}, [6](#cam41819-bib-0006){ref-type="ref"} Three classes of FCGR exist, encoded by related genes on the long arm of chromosome 1: *FCGR1*‐CD64; *FCGR2*‐CD32; and *FCGR3*‐CD16.[7](#cam41819-bib-0007){ref-type="ref"} Two polymorphisms located within coding regions of *FCGR2A* and *FCGR3A* were previously reported to be associated with the efficacy of cetuximab in colorectal cancer.[8](#cam41819-bib-0008){ref-type="ref"}, [9](#cam41819-bib-0009){ref-type="ref"} A nonsynonymous polymorphism in the extracellular domain of *FCGR2A* (rs1801274) changes the amino acid from histidine (H) to arginine (R), significantly reducing the receptor\'s affinity to Fc.[17](#cam41819-bib-0017){ref-type="ref"} The rs396991 polymorphism in *FCGR3A* is also found in the extracellular domain, leading either to a phenylalanine (F) or valine (V) substitution; this amino acid interacts with the lower hinge region of IgG1.[18](#cam41819-bib-0018){ref-type="ref"}, [19](#cam41819-bib-0019){ref-type="ref"} Previous studies of the association of these two polymorphisms with the efficacy of cetuximab reported mixed results.[8](#cam41819-bib-0008){ref-type="ref"}, [9](#cam41819-bib-0009){ref-type="ref"} Most of these studies had various limitations, including small sample size, non‐randomized patient selection, and suboptimal genotyping technique. A recent analysis of data from the Canadian Cancer Trials Group (CCTG) CO.17 randomized controlled trial found cetuximab treatment was associated with overall survival (OS) benefit in patients with metastatic wild‐type *KRAS* colorectal cancer who had the *FCGR2A* H/H genotype but not those with the R/‐ genotype. Patients with the H/R genotype had non‐statistically significant intermediate results.[20](#cam41819-bib-0020){ref-type="ref"} A *post hoc* analysis found cetuximab‐treated patients with the H/H genotype had longer OS than those with R/‐ genotype (univariate hazard ratio (HR) 0.63 (95% confidence interval (CI) 0.3‐0.9), adjusted HR: 0.57, 95% CI: 0.3‐0.8). This effect was not seen in the best supportive care arm. In contrast, no association was found between the *FCGR3A* polymorphism and any clinical outcome. The primary objective of this study was to replicate our previous finding of the association of *FCGR2A* polymorphism and OS in an independent, larger trial dataset after adjusting for other potential prognostic factors.

2. METHODS {#cam41819-sec-0006}
==========

2.1. Study design and population {#cam41819-sec-0007}
--------------------------------

This retrospective, secondary analysis of thegerm line polymorphisms *FCGR2A:H*→*R* (rs1801274, cytosine→thymine) and *FCGR3A:F*→*V* (rs396991, cytosine→adenine) in wild‐type *KRAS* patients used available DNA samples from the CCTG and the Australasian Gastro‐Intestinal Trials Group (AGITG) CO.20 trial.[21](#cam41819-bib-0021){ref-type="ref"} Briefly, this was a multicenter, open‐label, phase III randomized controlled trial; 750 chemotherapy‐refractory metastatic colorectal cancer patients were randomized (1:1) to cetuximab and placebo vs cetuximab and brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinase.[22](#cam41819-bib-0022){ref-type="ref"} Three months after study initiation, the protocol was amended to enroll only patients with wild‐type *KRAS,* given new information regarding the lack of benefit of anti‐EGFR monoclonal antibodies in *KRAS* mutant colorectal cancer.[2](#cam41819-bib-0002){ref-type="ref"} Twenty‐one patients with mutated *KRAS* and four patients with indeterminable *KRAS* status were enrolled prior to the amendment. Our analysis was conducted on known wild‐type *KRAS* patients only. Patients in both arms received cetuximab intravenously at an initial loading dose of 400 mg/m^2^ over 120 minutes, followed by a weekly maintenance infusion of 250 mg/m^2^ over 60 minutes. Patients randomly assigned to the combination arm also received oral brivanib at 800 mg on a daily schedule. No significant difference in the primary outcome of OS was observed (8.8 months vs 8.1 months in the brivanib and the placebo groups, respectively, HR: 0.88, 95% CI: 0.74‐1.03; *P* = 0.12), despite a strong progression‐free survival (PFS) benefit favoring the experimental arm with both cetuximab and brivanib (HR: 0.72; 95% CI: 0.62‐0.84; *P* \< 0.001).[21](#cam41819-bib-0021){ref-type="ref"}

2.2. Outcomes {#cam41819-sec-0008}
-------------

The primary objective of the current analysis was to evaluate the previously described association between *FCGR2A* polymorphism and OS in cetuximab‐treated patients. Exploratory objectives included the association of *FCGR2A* polymorphism and PFS and the associations of *FCGR3A* polymorphism and OS and PFS. OS was defined as the time from random assignment until death from any cause. PFS was defined as the time from random assignment until the first observation of disease progression or death from any cause. The CCTG trial database was used for all analyses. REMARK guidelines were followed.[23](#cam41819-bib-0023){ref-type="ref"} All outcomes were planned prior to analysis initiation.

2.3. DNA extraction and genotyping method {#cam41819-sec-0009}
-----------------------------------------

Whole blood samples from local sites were archived at the CCTG central tissue bank (Queen\'s University, Kingston, Canada). DNA was extracted using the Qiagen whole blood DNA Kit. DNA quantity (spectrophotometry) and quality (polymerase chain reactions) were checked.DNA was independently genotyped blindly in the laboratory of G. Liu using TaqMan assays ordered from Thermo Fisher scientific company (Waltham, MA, USA). Assay IDs were C_9077561_20 for rs1801274, and C_25815666_10 for rs396991, with a subset of 30 confirmed also by Sanger sequencing.[20](#cam41819-bib-0020){ref-type="ref"} Results were checked using Hardy‐Weinberg equilibrium testing.[24](#cam41819-bib-0024){ref-type="ref"} *KRAS* status was previously tested as a requirement for the CO.20 trial after the amendment.[21](#cam41819-bib-0021){ref-type="ref"}

2.4. Statistical analysis {#cam41819-sec-0010}
-------------------------

For the primary outcome analysis,*FCGR2A* polymorphism was compared with OS for all patients with genotyping results. Analyses were performed separately under the dominant, codominant, and additive genetic inheritance model assumptions; genotype was analyzed as a numerical variable for the additive model (number of copies of the minor allele), and as a categorical variable for the dominant and codominant models. The dominant genetic inheritance model was utilized for the primary analysis, consistent with our previous analysis.[20](#cam41819-bib-0020){ref-type="ref"} A formal power calculation for replication of our previous results under the dominant genetic inheritance model, assuming Hardy‐Weinberg equilibrium, found empirical power of 97.5% for the univariate HR and of 99.7% for the adjusted HR, at a significance level of 0.5%.[25](#cam41819-bib-0025){ref-type="ref"} For the exploratory analyses, *FCGR2A* polymorphism was compared with PFS, and *FCGR3A* polymorphism was compared with OS and PFS. Interaction between *FCGR2A* and *FCGR3A* polymorphisms was explored by comparing outcomes of patients with both H/H*FCGR2A and* F/F *FCGR3A* polymorphisms to those with the R/R and V/V polymorphisms and to the rest of the study cohort, as a recent meta‐analysis found the F/F *FCGR3A* genotype was associated with better OS.[12](#cam41819-bib-0012){ref-type="ref"} Additional exploratory analyses assessed potential relationships of *FCGR2A* and *FCGR3A* polymorphisms with toxicity. OS and PFS were assessed using Kaplan‐Meier curves, log‐rank tests (univariable analyses), and Cox proportional hazard models in multivariable analyses, adjusting for clinically relevant factors identified in the original trial analysis, including age, gender, side of primary tumor, stage, grade, number of metastatic sites, serum lactate dehydrogenase concentration, and treatment arm.[21](#cam41819-bib-0021){ref-type="ref"} Genomewide association studies (GWAS) generated a principal component analysis that was used to adjust for population stratification in the multivariable analyses. Tests for the assumption of proportional hazards were performed. R software version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses.

3. RESULTS {#cam41819-sec-0011}
==========

3.1. Patient and genotyping characteristics {#cam41819-sec-0012}
-------------------------------------------

The CO.20 trial included 725 patients who were known to be wild‐type *KRAS*, of whom 595 (82%) had provided consent for genotyping and had available DNA extracted from an EDTA‐treated whole blood sample. A total of 592 (99.4%) were successfully genotyped for *FCGR2A* and 594 (99.8%) for *FCGR3A*. The consort diagram of samples is shown in Figure [1](#cam41819-fig-0001){ref-type="fig"}. Demographic and disease variables are summarized in Table [1](#cam41819-tbl-0001){ref-type="table"}. A total of 165 patients (28%) had the H/H *FCGR2A* genotype, 299 (50%) had H/R, and 128 (22%) had R/R A total of 232 (39%) patients had the F/F *FCGR3A* genotype, 275 (46%) had F/V, and 87 (15%) had V/V. Both polymorphisms were in Hardy‐Weinberg equilibrium: *P* = 0.73 (*FCGR2A*) and *P* = 0.71 (*FCGR3A*). Linkage disequilibrium between *FCGR2A* and *FCGR3A* was low (*r* ^2 ^= 0.03, *D*′ = 0.25). Patient characteristics were not significantly associated with *FCGR2A* polymorphisms (Table [1](#cam41819-tbl-0001){ref-type="table"}) and were also comparable between the subsets of patients with or without genotyping data (Table [S1](#cam41819-sup-0002){ref-type="supplementary-material"}). Distribution of *FCGR2A* and *FCGR3A* genotypes was comparable in the brivanib and control study arms (Table [S2](#cam41819-sup-0003){ref-type="supplementary-material"}). There was 100% concordance between the TaqMan assays and the Sanger sequencing.

![CONSORT diagram](CAM4-7-5478-g001){#cam41819-fig-0001}

###### 

Patient characteristics according to *FCGR2A* polymorphism

  Characteristics                            Genotyped patients (n = 592)   *FCGR2A* H/H (n = 165)   *FCGR2A* H/R (n = 299)   *FCGR2A* R/R (n = 128)   *P*‐value
  ------------------------------------------ ------------------------------ ------------------------ ------------------------ ------------------------ -----------
  Mean age, y (SD)                           62.8 (10.7)                    62.4 (11.1)              63 (10)                  62.9 (12.1)              0.64
  Male gender                                392 (66%)                      115 (70%)                190 (64%)                87 (68%)                 0.37
  Side of primary cancer                                                                                                                               
  Left                                       261 (44%)                      74 (45%)                 134 (45%)                53 (41%)                 0.25
  Right                                      125 (21%)                      26 (16%)                 66 (22%)                 33 (26%)                 
  Rectal                                     206 (35%)                      65 (39%)                 99 (33%)                 42 (33%)                 
  Tumor stage at initial diagnosis                                                                                                                     
  I/II                                       70 (12%)                       28 (18%)                 29 (10%)                 13 (11%)                 0.091
  III                                        175 (31%)                      52 (32%)                 83 (29%)                 40 (33%)                 
  IV                                         325 (57%)                      80 (50%)                 177 (61%)                68 (56%)                 
  Missing                                    22                             5                        10                       7                        
  Tumor grade                                                                                                                                          
  I                                          35 (6%)                        9 (6%)                   22 (8%)                  4 (4%)                   0.078
  II                                         421 (78%)                      128 (83%)                214 (77%)                79 (72%)                 
  III                                        86 (16%)                       17 (11%)                 42 (15%)                 27 (25%)                 
  Missing                                    50                             11                       21                       18                       
  Number of metastatic sites                                                                                                                           
  ≤2                                         468 (79%)                      135 (82%)                231 (77%)                102 (80%)                0.52
  \>2                                        124 (21%)                      30 (18%)                 68 (23%)                 26 (20%)                 
  Number of previous lines of chemotherapy                                                                                                             
  ≤2                                         22 (4%)                        6 (4%)                   9 (3%)                   7 (5%)                   0.44
  \>2                                        570 (96%)                      159 (96%)                290 (97%)                121 (95%)                

SD, standard deviation.

John Wiley & Sons, Ltd

3.2. Association between FCGR2A polymorphisms and OS {#cam41819-sec-0013}
----------------------------------------------------

All Cox models were consistent with the assumption of proportional hazards. There was a statistically significant association between *FCGR2A* genotype and OS in the study cohort (Table [2](#cam41819-tbl-0002){ref-type="table"}). In the primary univariable analysis under the dominant inheritance model, the H/H genotype was associated with better OS than the R/‐ genotype (HR: 0.61, 95% CI: 0.5‐0.74, *P* \< 0.001, median absolute benefit 1.3 months; Figure [2](#cam41819-fig-0002){ref-type="fig"}). Similar results were obtained in the exploratory analyses under the additive model (OR: 0.71 per H allele, 95% CI: 0.63‐0.8, *P* \< 0.001) and the codominant model, with the H/H genotype associated with better OS compared with the R/R genotype (HR: 0.51, 95% CI: 0.4‐0.65, *P* \< 0.001, median absolute benefit 3.7 months), and intermediate outcomes for patients with the H/R genotype (HR: 0.65, 95% CI: 0.53‐0.8, *P* \< 0.001; Figure [3](#cam41819-fig-0003){ref-type="fig"}). Results remained significant in multivariable analysis under all models (Table [2](#cam41819-tbl-0002){ref-type="table"}). There was no interaction between *FCGR2A* polymorphism and OS according to treatment arm (*P* = 0.37).

###### 

Primary and exploratory multivariable analyses of the association between *FCGR2A* polymorphism and overall survival

  Genetic inheritance model   Genotype   Median survival (mo)   One‐year survival (95% CI)   Two‐year survival (95% CI)   aHR (95% CI)                  *P*‐value
  --------------------------- ---------- ---------------------- ---------------------------- ---------------------------- ----------------------------- -----------
  Primary analysis                                                                                                                                      
  Dominant                    H/H        9.6                    44% (37‐52)                  18% (13‐26)                  0.66 (0.54‐0.81)              \<0.001
  R/‐                         8.3        32% (27‐37)            4% (2‐8)                     Reference                                                  
  Exploratory analyses                                                                                                                                  
  Codominant                  H/H        9.6                    44% (37‐52)                  18% (13‐26)                  0.53 (0.41‐0.68)              \<0.001
  H/R                         9.3        34% (29‐40)            5% (3‐8)                     0.72 (0.58‐0.89)             0.003                         
  R/R                         5.9        27% (21‐36)            3% (1‐8)                     Reference                                                  
  Additive                    H/H        9.6                    44% (37‐52)                  18% (13‐26)                  Per increase in 1 wild‐type   \<0.001
  H/R                         9.3        34% (29‐40)            5% (3‐8)                     H allele: 0.72 (0.64‐0.83)                                 
  R/R                         5.9        27% (21‐36)            3% (1‐8)                                                                                

Analyses are adjusted for clinically relevant factors identified in the original trial analysis.[21](#cam41819-bib-0021){ref-type="ref"} Genomewide association studies (GWAS), used for population stratification, were available for 566 of the 592 (95.6%) patients with genotyping results, and subset analyses of these 566 patients that included adjustment by principal components found virtually identical results.

aHR, adjusted hazard ratio from Cox proportional hazards models; CI, confidence interval.
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![Kaplan‐Meier curves for overall survival by *FCGR2A* and *FCGR3A* polymorphisms under the dominant genetic model assumptions](CAM4-7-5478-g002){#cam41819-fig-0002}

![Kaplan‐Meier curves for overall survival by *FCGR2A* and *FCGR3A* polymorphisms under the codominant genetic model assumptions](CAM4-7-5478-g003){#cam41819-fig-0003}

3.3. Exploratory associations between FCGR polymorphisms and clinical outcomes {#cam41819-sec-0014}
------------------------------------------------------------------------------

There was a statistically significant association between *FCGR2A* genotype and PFS in the study cohort. In univariable analysis under the dominant inheritance model, the H/H genotype was associated with better PFS compared with the R/‐ genotype (HR: 0.80, 95% CI: 0.67‐0.95, *P* = 0.01, median absolute benefit 1.6 months). Similar results were obtained under the additive inheritance model (OR: 0.80 per H allele, 95% CI: 0.71‐0.9, *P* \< 0.001) and under the codominant model, with the H/H genotype associated with better PFS than patients with the R/R genotype (HR: 0.63, 95% CI: 0.5‐0.8, *P* \< 0.001, median absolute benefit 3.3 months) and similar PFS compared with the H/R genotype (HR: 0.87, 95% CI: 0.71‐1.05, *P* = 0.14; Figure [S1](#cam41819-sup-0001){ref-type="supplementary-material"}). Results remained significant in multivariable analysis under all models (Table [3](#cam41819-tbl-0003){ref-type="table"}). There was no interaction between *FCGR2A* polymorphism and PFS according to treatment arm (*P* = 0.65).

###### 

Exploratory multivariable analysis of the associations between the *FCGR2A* and *FCGR3A* polymorphisms and clinical outcomes

  Polymorphism                                              Genotype                                                  Median survival (mo)        Codominant model: aHR (95% CI), *P*‐value   Additive model: aHR (95% CI), *P*‐value                           Dominant model: aHR (95% CI), *P*‐value
  --------------------------------------------------------- --------------------------------------------------------- --------------------------- ------------------------------------------- ----------------------------------------------------------------- ------------------------------------------
  Overall survival                                                                                                                                                                                                                                              
  *FCGR3A*                                                  F/F                                                       8.6                         1.03 (0.78‐1.35), 0.84                      Per increase in 1 wild‐type F allele: 0.99 (0.87‐1.12), 0.80      F/F vs V/‐: 0.93 (0.78‐1.11), *P* = 0.44
  F/V                                                       8.8                                                       0.91 (0.75‐1.09), 0.30                                                                                                                    
  V/V                                                       9.5                                                       reference                                                                                                                                 
  *FCGR2A* and *FCGR3A* genotype combinations               H/H + F/F[\[Link\]](#cam41819-note-0009){ref-type="fn"}   13.7                        0.33 (0.16‐0.68), 0.003                     Not applicable                                                    Not applicable
  Others                                                    8.7                                                       0.52 (0.36‐0.75), \<0.001                                                                                                                 
  R/R + V/V[\[Link\]](#cam41819-note-0010){ref-type="fn"}   1.2                                                       Reference                                                                                                                                 
  Progression‐free survival                                                                                                                                                                                                                                     
  *FCGR2A*                                                  H/H                                                       5.2                         0.65 (0.51‐0.83), \<0.001                   Per increase in 1 wild‐type H allele: 0.81 (0.72‐0.92), \<0.001   H/H vs R/‐: 0.80 (0.66‐0.97), *P* = 0.02
  H/R                                                       3.7                                                       0.87 (0.71‐1.05), 0.15                                                                                                                    
  R/R                                                       1.9                                                       Reference                                                                                                                                 
  *FCGR3A*                                                  F/F                                                       3.7                         0.99 (0.76‐1.28), 0.92                      Per increase in 1 wild‐type F allele: 0.97 (0.86‐1.1), 0.64       F/F vs V/‐: 0.93 (0.78‐1.1), *P* = 0.39
  F/V                                                       3.6                                                       0.91 (0.76‐1.09), 0.31                                                                                                                    
  V/V                                                       5.1                                                       Reference                                                                                                                                 
  *FCGR2A* and *FCGR3A* genotype combinations               H/H + F/F[\[Link\]](#cam41819-note-0009){ref-type="fn"}   5.5                         0.45 (0.22‐0.92), 0.03                      Not applicable                                                    Not applicable
  Others                                                    3.6                                                       0.79 (0.58‐1.09), 0.15                                                                                                                    
  R/R + V/V[\[Link\]](#cam41819-note-0010){ref-type="fn"}   1.0                                                       Reference                                                                                                                                 

Analyses are adjusted for clinically relevant factors identified in the original trial analysis.[21](#cam41819-bib-0021){ref-type="ref"} Genomewide association studies (GWAS), used for population stratification, were available for 566 of the 592 (95.6%) patients with genotyping results, and subset analyses of these 566 patients that included adjustment by principal components found virtually identical results.

aHR, adjusted hazard ratio from Cox proportional hazards models; CI, confidence interval.

Double wild‐type genotype (wild type for both *FCGR2A* and *FCGR3A*).

Double‐homozygous variant genotype (homozygous variant for both *FCGR2A* and *FCGR3A*).
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No association was observed between *FCGR3A* polymorphism and OS (Table [3](#cam41819-tbl-0003){ref-type="table"}, Figures [2](#cam41819-fig-0002){ref-type="fig"} and [3](#cam41819-fig-0003){ref-type="fig"}) or PFS (Table [3](#cam41819-tbl-0003){ref-type="table"}, Figure [S1](#cam41819-sup-0001){ref-type="supplementary-material"}). However, when combinations of genotypes of *FCGR2A* and *FCGR3A* polymorphisms were compared with OS and PFS both in univariable analysis and adjusted for key known prognostic factors, patients with both the H/H *FCGR2A* and the F/F*FCGR3A* double wild‐type genotypes had significantly better OS compared to those with the R/R and V/V polymorphisms (HR: 0.33, 95% CI: 0.16‐0.68, *P* = 0.003; median absolute benefit, 12.5 months) and those with any other genotype (Table [3](#cam41819-tbl-0003){ref-type="table"}, Figure [3](#cam41819-fig-0003){ref-type="fig"}).

3.4. Exploratory association between FCGR polymorphisms and toxicity {#cam41819-sec-0015}
--------------------------------------------------------------------

There was no association between *FCGR2A* (*P* = 0.13) or *FCGR3A* (*P* = 0.64) and any grade 3 or greater treatment toxicity in multivariable analysis. A pre‐specified analysis of the interaction between *FCGR2A* and *FCGR3A* polymorphisms and skin rash also found no statistically significant interaction, *P* = 0.20 and *P* = 0.71, respectively. Exploratory analyses further found virtually identical relationships in subset analyses by trial arm.

4. DISCUSSION {#cam41819-sec-0016}
=============

We have successfully replicated our previous results demonstrating an association between *FCGR2A* genotype and survival in wild‐type *KRAS* colorectal cancer patients treated with cetuximab. H/H genotype was associated with significantly longer OS than the R/‐ genotype under the dominant genetic model assumptions. Additional exploratory analyses under the additive and codominant genetic inheritance models found intermediate results for patients with the heterozygous genotype; this finding expands on the prior study which had too small a sample size to adequately assess these models. The similar and consistently significant results under the additive and codominant genetic inheritance models imply that the clinical benefit for colorectal cancer patients treated with cetuximab could be additive in nature, with an improvement of approximately \~30% in survival benefit for every H allele of *FCGR2A*.

The large sample size was also used to explore the joint effect of both *FCGR2A* and *FCGR3A* polymorphisms together; we found that the best outcomes were in patients with the double wild‐type genotypes and the worst were found in the 2% of patients with the double‐homozygous variant genotypes, with a threefold difference in OS (absolute median difference 12.5 months) after adjustment for other prognostic factors, although confidence intervals were wide. As the presence of both homozygous variants is a rare occurrence, the additional clinical utility of this finding is limited. However, it provides further insight into the mechanistic role of *FCGR* polymorphisms in clinical outcomes of cetuximab‐treated, metastatic colorectal cancer, namely, the role of *FCGR3A* polymorphism in modifying the primary relationship between *FCGR2A* and clinical outcomes.

Regardless, the primary clinical implication of this study relates to the common variant allele frequency of the *FCGR2A* polymorphism[26](#cam41819-bib-0026){ref-type="ref"}: OS was twice longer for patients with the *FCGR2A* H/H polymorphism than those with the R/R genotype, corresponding to median absolute difference of 3.7 months in the patient population now known to benefit from cetuximab, namely *KRAS* wild‐type patients. Of additional importance is that genotypes associated with better OS were not associated with higher rates of grade 3 or greater toxicity, nor were they related to skin toxicity. This is likely due to the different mechanisms involved: Toxicity is thought to be mediated through competitive inhibition of the EGFR receptor,[27](#cam41819-bib-0027){ref-type="ref"}, [28](#cam41819-bib-0028){ref-type="ref"} a different mechanism of action from Fc‐γ receptor‐regulated ADCC.[3](#cam41819-bib-0003){ref-type="ref"}, [4](#cam41819-bib-0004){ref-type="ref"} No interaction was found between treatment arm and the analyzed polymorphisms, which was to be expected as both treatment arms included the same cetuximab regimen, and brivanib efficacy was not expected to be affected by FCGR polymorphisms.

Although our findings replicate the results of several prior publications[8](#cam41819-bib-0008){ref-type="ref"}, [14](#cam41819-bib-0014){ref-type="ref"}, [15](#cam41819-bib-0015){ref-type="ref"} and of our previous analysis,[20](#cam41819-bib-0020){ref-type="ref"} others have reported different results. Notably, a recent consortium analysis of 660 cetuximab‐treated patients with wild‐type *KRAS* metastatic colorectal carcinoma did not find any association between *FCGR2A* polymorphisms and clinical outcome.[16](#cam41819-bib-0016){ref-type="ref"} However, the study population was heterogeneous in regard to the studied intervention, with a minority of the patients treated with single‐agent cetuximab, and most patients treated with irinotecan‐based regimens that included cetuximab.[16](#cam41819-bib-0016){ref-type="ref"} Also, only approximately a third of the patients had available germ line DNA from blood samples, with the rest of the patients having putatively normal DNA extracted from formalin‐fixed paraffin‐embedded (FFPE) slides,[16](#cam41819-bib-0016){ref-type="ref"} an approach that has been demonstrated to be unreliable for at least some genes.[30](#cam41819-bib-0030){ref-type="ref"} Both of our studies were conducted in relatively homogenous and prospective patient populations with germ line DNA genotyped from blood samples, and the results replicated.[23](#cam41819-bib-0023){ref-type="ref"}

While the *FCGR2A* wild‐type genotype was associated with better OS and PFS, this study\'s results were of greater magnitude for OS, consistent with our previous findings in CO.17,[20](#cam41819-bib-0020){ref-type="ref"} and with several large studies of anti‐EGFR mAbs for wild‐type *KRAS* colorectal cancer, such as the FIRE‐3 and the PEAK trials.[31](#cam41819-bib-0031){ref-type="ref"}, [32](#cam41819-bib-0032){ref-type="ref"} Although OS can be confounded by post‐trial treatments, it is less likely to be affected by pre‐trial confounders, given the randomized nature of these trials. An alternative explanation might be a joint effect between *FCGR* polymorphisms and anti‐EGFR mAbs, untested in the aforementioned trials and identified in this trial, causing failure of surrogacy of PFS for OS.

Similar interactions between *FCGR2A* polymorphism and clinical outcomes have been reported for other mAbs and malignancies. Patients with germ line H/H polymorphism treated with the anti‐human epidermal growth factor receptor 2 (HER2) mAb trastuzumab for early HER2‐positive breast cancer were more likely to achieve pathological response while those with metastatic disease had better objective response rate and PFS.[33](#cam41819-bib-0033){ref-type="ref"}, [34](#cam41819-bib-0034){ref-type="ref"} The H/H polymorphism of *FCGR2A* was also associated with better response to anti‐TNF mAbs in patients with rheumatoid arthritis.[36](#cam41819-bib-0036){ref-type="ref"}, [37](#cam41819-bib-0037){ref-type="ref"} This evidence further supports a genetic role in determining cetuximab treatment outcomes.

Limitations of this study include an inability to genotype the entire sample as the blood sample component of the CO.20 trial was voluntary. However, the genotyped subgroup represented 79% of the entire trial population, with similar clinical and demographic characteristics (Table [S1](#cam41819-sup-0002){ref-type="supplementary-material"}). Wild‐type *KRAS* status was defined based on the assessment of lack of mutations seen in exon 2; the effect of other, significantly rarer *RAS* and *BRAF* mutations on this polymorphism‐outcome association, was not assessed in this analysis.[40](#cam41819-bib-0040){ref-type="ref"} EGFR polymorphisms previously reported to be associated with cetuximab efficacy and toxicity were also not assessed.[41](#cam41819-bib-0041){ref-type="ref"}, [42](#cam41819-bib-0042){ref-type="ref"} Finally, although we could perform joint analyses of combinations of *FCGR2A* and *FCGR3A* genotypes, we still had an insufficient sample size to perform a formal interaction analysis.

In conclusion, this analysis confirms that *FCGR2A* H/H polymorphism in patients with wild‐type *KRAS* metastatic colorectal cancer treated with cetuximab is associated with significantly longer OS without affecting toxicity profiles. This association may be modified by the *FCGR3A* polymorphism*,* as patients with the double wild‐type genotypes of H/H and F/F genotypes had the best clinical outcomes. This replication in a large, separate dataset provides evidence to evaluate prospectively the utility of *FCGR* polymorphisms as biomarkers for clinical management in this patient population.
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